... and my final question, could this new partership in anyway conflict with our (the Biocurex shareholders) belief that Abbott recognizes Recaf as being a premier univeral cancer marker? Keep in mind that Breast cancer results have shown a better that 95% accuracy rate for both specificity and sensitivity, and I happen to know for sure, that Abbott knows that!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.